|
|
 |
|
INTENDED AUDIENCE: Physicians, Physician assistants, nurses, nurse practitioners and advanced practice nurses, pharmacists and dentists involved in the treatment and care of persons infected with the HIV virus.
EDUCATIONAL OBJECTIVES: Upon completion of this monograph, the participant should be able to:
- Understand the mechanism of action and the role of the protease inhibitors in the combination antiretroviral treatment called “HAART”, highly active antiretroviral therapy.
- Understand the dosages, dose requirements (food and hydration) of each agent.
- Understand the side effects, short-term and long-term toxicities of the protease inhibitors and how to manage these.
- Understand the long-term complications and class adverse effects of the protease inhibitors and product selection in individual patients with co-morbities along with HIV infection.
Purpose: The advent of the protease inhibitors towards the end of 1995 revolutionized the drug management of HIV disease. Beginning with saquinavir mesylate, a poorly bio-available compound which was first released as the hard gel capsule (Invirase) and subsequently improved by a soft gel formulation (Fortovase), the protease inhibitors in combination with the reverse transcriptase inhibitors, provided HIV clinicians, for the first time with regimens described as “highly active antiretroviral therapy” or HAART and led to dramatic reductions in mortality due to this virus. Today, there are 5 single-ingredient protease inhibitors with one fixed combination boosted PI, (lopinavir ritonavir, as Kaletra) providing numerous possibilities for single and boosted protease inhibitor containing regimens The highlights of each of these antiretroviral agents will be presented.
ACCREDITATION: this material, at the point of presentation, will be approved for continuing education credit by the American Council on Medical Education (CME), the American Council of Nursing Education and the American Council of Pharmaceutical Education (ACPE).
DISCLOSURE
In accordance with the Accreditation Council for Continuing Medical and Pharmaceutical education Standards for Commercial Support, the Course Director for this activity has been asked to complete a disclosure form. Disclosures are described below:
Dr. Tina Edmunds-Ogbuokiri, Pharm.D., FASCP
Associate Professor of Clinical Pharmacy, Xavier University of Louisiana College of Pharmacy and Consultant Clinical Pharmacist, HIV Outpatient Clinic, 136 S. Roman Street, Medical Center of Louisiana at New Orleans.
Grant/Research Support: National Minority AIDS Education and Training Center, Funding Agency Grant Number: 1H4A HA 00066-01. |
|
|
Transcriptase 
